Search results
Showing 61 to 64 of 64 results for hepatocellular carcinoma
Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)
This guidance has been replaced by NICE technology appraisal guidance 474.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
This guidance has been updated and replaced by NICE technology appraisal guidance 849.
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition